| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |